Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.

Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis. Skin Therapy Lett. 2017 Mar;22(2):1-7 Authors: Gupta AK, Cernea M, Lynde CW Abstract Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis. Tofacitinib inhibits Janus kinases (JAKs), which are essential for the signaling of multiple inflammatory pathways and have been implicated in the pathogenesis of RA and psoriasis. The efficacy and safety of tofacitinib in the treatment of RA and psoriasis have been demonstrated in Phase III trials. Across all studies, the efficacy of tofacitinib in alleviating symptoms of RA and psoriasis were superior to placebo. Moreover, treatment was generally well-tolerated, with the most frequently reported adverse events, for both RA and psoriasis, being nasopharyngitis and upper respiratory tract infection. As such, tofacitinib proves to be an effective therapeutic option for RA and a promising new therapy for psoriasis. PMID: 28329404 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

ConclusionsThe updated recommendations of the Mexican College of Rheumatology on the pharmacological treatment of rheumatoid arthritis incorporate the best available information to be used in the Mexican health care system.ResumenLos avances terapéuticos en la artritis reumatoide obligan a revisión periódica de las guías de tratamiento.ObjetivoActualizar las guías del Colegio Mexicano de Reumatología del tratamiento farmacológico de la artritis reumatoide.MétodoParticiparon reumatólogos certificados de diferentes instituciones de salud y regiones del paí...
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
Publication date: Available online 12 November 2019Source: Journal of OrthopaedicsAuthor(s): Roshan Wade, Swapneel Shah, B.S. Sujith, Kunal Shah, Aditya Raj, Nandan MaratheAbstractThe technique of high tibial osteotomy (HTO) was traditionally documented for symptomatic medial tibiofemoral arthrosis associated with coronal plane malalignment in a stable knee. , recently, more attention has been given to the treatment of coronal malalignment in lax knees with HTO with or without ligament reconstruction.Patients with overwhelming pain, chronic ligament deficiency and coronal or sagittal deformity are generally easier to treat...
Source: Journal of Orthopaedics - Category: Orthopaedics Source Type: research
This study is registered with the Netherlands Trial Registry, number NTR5263.FindingsWe screened patients for enrolment between Dec 3, 2015, and May 31, 2018. Patients completed baseline visits and started treatment between Dec 14, 2015, and July 2, 2018, and the last study visit of the last patient was Oct 4, 2018. Of 149 patients assessed for eligibility, 57 (38%) patients were excluded (predominantly because they did not meet one or several inclusion criteria, most often because of an absence of synovial inflammation or of flare-ups after NSAID washout) and 92 (62%) patients were eligible for inclusion. We randomly assi...
Source: The Lancet - Category: General Medicine Source Type: research
Osteoarthritis is a degenerative joint disease that is the most common type of arthritis. Usually, it occurs among people of advanced age. But it can begin in middle age or even sooner, especially if there’s been an injury to the joint. While there are treatments available — exercise, braces or canes, loss of excess weight, various pain relievers and anti-inflammatory medicines — these are no cures, and none of the treatments are predictably effective. In fact, often they don’t work at all, or help only a little. Injected steroids or synthetic lubricants can be tried as well. When all else fails, jo...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Arthritis Bones and joints Complementary and alternative medicine Pain Management Source Type: blogs
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
AbstractIntroductionRheumatoid arthritis (RA) is a chronic systemic auto-immune disease associated with a prothrombotic state. Tocilizumab, an interleukin-6 receptor inhibitor, is highly effective in controlling disease activity and thrombotic risk. Factor XIII (FXIII), involved in thrombotic complications, has been reported to be reduced in RA patients during maintenance treatment with tocilizumab, but no data are available before and after the drug administration. Thus, we investigated the effects of tocilizumab on FXIII, thrombin generation and inflammation in patients with RA na ïve for the drug.MethodsWe studied ...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
AbstractPurposePainful and slow recovery are the presumed disadvantages after opening-wedge high tibial osteotomy (HTO) and play a role in favouring arthroplasty as treatment for moderate isolated medial knee arthritis. The primary study objective was to investigate the effect of press-fit structural impacted bone allograft with locking plate fixation on early ambulation, postoperative pain levels, and resumption of daily-life activities in opening-wedge HTO.MethodsA prospective consecutive opening-wedge HTO case series was conducted, including 103 patients with final follow-up at 1  year. Weight-bearing was allowed f...
Source: Knee Surgery, Sports Traumatology, Arthroscopy - Category: Orthopaedics Source Type: research
Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis and in clinical trials for psoriasis. In clinical trials investigating the therapeutical effects of tofacitinib, the most common adverse events observed were nasopharyngitis and upper respiratory tract infections. JAKs are found downstream of the type II cytokine receptor family. Many cytokines produced by TH17 cells stimulate their target cells via the type II cytokine receptors and these receptors use the JAK pathway for signal transduction.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Pharmacology and Drug Development Source Type: research
AbstractPsoriasis is a common, chronic, immune-mediated, inflammatory skin disease with systemic involvement and significant impact on patients ’ quality of life. Several biologic treatments have been developed in recent decades, such as tumor necrosis factor (TNF)-α inhibitors, a non-selective interleukin (IL)-23 inhibitor (ustekinumab, which also inhibits IL-12), and—most recently—IL-17 inhibitors. Guselkumab is a novel biological therapy that selectively targets IL-23 and is the first-in-class selective IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis. These inhibitors are ex...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Common Cold | Dermatology | Psoriasis | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | Skin | Study